Imetelstat

Intervention Approved

2 papers2 findings

1 lab in 1 country

Funders: Geron Corporation and 1 more
2 of 2 findings with company ties

Human trial1

Outcomes

2

Red blood cell transfusion independence

upin humans1

1 study

Imetelstat improves red blood cell transfusion independence in humans.
“imetelstat, demonstrated significantly higher rates of red blood cell (RBC) transfusion independence (TI) versus placebo”
Human trialin non-del(5q), RBC transfusion-dependent LR-MDS
Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat
Leukemia12 Jan 2026

Variant allele frequency

downin humans1

1 study

Imetelstat decreases variant allele frequency in humans.
“patients treated with imetelstat had greater sustained reductions in variant allele frequency of multiple mutations versus placebo recipients”
Human trialin non-del(5q), RBC transfusion-dependent LR-MDS
Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat
Leukemia12 Jan 2026

More on Variant allele frequency

Development

Companies: GeronApprovedmyelodysplastic syndromes, myelofibrosis

Latest

2 in 12 months

Bulletin du CancerYesterday

Recommendations of the Groupe Francophone des Myélodysplasies (GFM) - Diagnostic approach and management of myelodysplastic syndromes, chronic myelomonocytic leukemias, and VEXAS syndrome

ReviewIndustry & policy

Leukemia12 Jan

Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat

Randomised trial in peopleMyelodysplastic syndrome